CN104302311A - 成纤维细胞生长因子21蛋白质的治疗用途 - Google Patents

成纤维细胞生长因子21蛋白质的治疗用途 Download PDF

Info

Publication number
CN104302311A
CN104302311A CN201380025338.6A CN201380025338A CN104302311A CN 104302311 A CN104302311 A CN 104302311A CN 201380025338 A CN201380025338 A CN 201380025338A CN 104302311 A CN104302311 A CN 104302311A
Authority
CN
China
Prior art keywords
seq
bone
fgf21 protein
fgf21
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380025338.6A
Other languages
English (en)
Chinese (zh)
Inventor
Y·L·马
A·R·伊里萨里罗维拉
V·L·雷诺兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104302311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104302311A publication Critical patent/CN104302311A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380025338.6A 2012-05-15 2013-05-09 成纤维细胞生长因子21蛋白质的治疗用途 Pending CN104302311A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US61/646,974 2012-05-15
US201361786939P 2013-03-15 2013-03-15
US61/786,939 2013-03-15
PCT/US2013/040275 WO2013173158A1 (en) 2012-05-15 2013-05-09 Therapeutic uses of fibroblast growth factor 21 proteins

Publications (1)

Publication Number Publication Date
CN104302311A true CN104302311A (zh) 2015-01-21

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380025338.6A Pending CN104302311A (zh) 2012-05-15 2013-05-09 成纤维细胞生长因子21蛋白质的治疗用途

Country Status (21)

Country Link
US (1) US20150141335A1 (https=)
EP (1) EP2852398A1 (https=)
JP (1) JP2015522539A (https=)
KR (1) KR20150002801A (https=)
CN (1) CN104302311A (https=)
AU (1) AU2013263188A1 (https=)
BR (1) BR112014028413A2 (https=)
CA (1) CA2869320A1 (https=)
CL (1) CL2014002846A1 (https=)
CO (1) CO7131381A2 (https=)
EA (1) EA201491856A1 (https=)
HK (1) HK1202800A1 (https=)
IL (1) IL235482A0 (https=)
MA (1) MA37506B1 (https=)
MX (1) MX2014013913A (https=)
PE (1) PE20142432A1 (https=)
PH (1) PH12014502537A1 (https=)
SG (1) SG11201407655TA (https=)
TN (1) TN2014000409A1 (https=)
WO (1) WO2013173158A1 (https=)
ZA (1) ZA201407532B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108324928A (zh) * 2018-03-05 2018-07-27 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10293026B2 (en) 2014-09-08 2019-05-21 Osaka University Agent for preventing or treating demyelinating disease
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3935075A4 (en) 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. POLYPEPTIDE MOLECULE AND APPLICATION THEREOF
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906530A (zh) * 2011-10-04 2014-07-02 伊莱利利公司 成纤维细胞生长因子21变体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501407B (zh) * 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906530A (zh) * 2011-10-04 2014-07-02 伊莱利利公司 成纤维细胞生长因子21变体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FAZELI ET AL: "SerumFGF-21 levels are associated with worsened radial trabecular bone microarchitecture and decreased radial bone strength in women with anorexia nervosa", 《BONE》 *
LEE ET AL.: "Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?", 《OSTEOPOROS INT》 *
LI ET AL.: "fibroblast grow factor 21 concentration in serum and synovial fluid is associated with radiographic bone loss of knee osteoarthritis", 《SCAND J CLIN LAB INVEST》 *
WEI WEI ET AL.: "fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome profliferator-activated receptor gamma", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》, 29 February 2012 (2012-02-29), pages 3143 - 3148, XP002712351, DOI: 10.1073/pnas.1200797109 *
WU ET AL: "Fibroblast Growth Factor 21 (FGF21) Inhibits Chondrocyte Functio", 《J BIOL CHEM》 *
ZHANG ET AL.: "The starvation hormone, fibroblastgrowth factor-21, extends lifespan in mice Yuan Zhang et al", 《ELIFE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108324928A (zh) * 2018-03-05 2018-07-27 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用

Also Published As

Publication number Publication date
SG11201407655TA (en) 2014-12-30
CO7131381A2 (es) 2014-12-01
CL2014002846A1 (es) 2015-01-30
CA2869320A1 (en) 2013-11-21
EA201491856A1 (ru) 2015-03-31
EP2852398A1 (en) 2015-04-01
AU2013263188A1 (en) 2014-10-16
ZA201407532B (en) 2016-05-25
HK1202800A1 (en) 2015-10-09
JP2015522539A (ja) 2015-08-06
PE20142432A1 (es) 2015-01-22
PH12014502537A1 (en) 2015-01-21
MA37506A1 (fr) 2016-01-29
TN2014000409A1 (en) 2015-12-21
US20150141335A1 (en) 2015-05-21
BR112014028413A2 (pt) 2017-11-07
KR20150002801A (ko) 2015-01-07
MA37506B1 (fr) 2017-03-31
IL235482A0 (en) 2014-12-31
MX2014013913A (es) 2015-02-17
WO2013173158A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
CN104302311A (zh) 成纤维细胞生长因子21蛋白质的治疗用途
Ornitz et al. Achondroplasia: development, pathogenesis, and therapy
Drake et al. Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned
Varela et al. One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption
Sims et al. Interleukin‐11 receptor signaling is required for normal bone remodeling
Ominsky et al. Sustained modeling‐based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab
Takyar et al. EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone
Lozano et al. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia
Ansari et al. Autocrine and paracrine regulation of the murine skeleton by osteocyte‐derived parathyroid hormone‐related protein
Sabir et al. The evolving therapeutic landscape of genetic skeletal disorders
Stensen et al. GIP and the gut-bone axis–physiological, pathophysiological and potential therapeutic implications
Clowes et al. Potential role of pancreatic and enteric hormones in regulating bone turnover
Papapoulos Targeting sclerostin as potential treatment of osteoporosis
Robling et al. Anabolic and catabolic regimens of human parathyroid hormone 1–34 elicit bone-and envelope-specific attenuation of skeletal effects in Sost-deficient mice
Cheng et al. Calcium‐sensing receptors in chondrocytes and osteoblasts are required for callus maturation and fracture healing in mice
Thomas Intermittent parathyroid hormone therapy to increase bone formation
US20030109537A1 (en) Methods and materials for treating bone conditions
Yavropoulou et al. Incretins and bone: evolving concepts in nutrient-dependent regulation of bone turnover
Luo et al. Progesterone upregulates TGF-b isoforms (b1, b2, and b3) expression in normal human osteoblast-like cells
Clines et al. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor
Noda et al. Osteopontin
Mentaverri et al. Potential anti-catabolic and anabolic properties of strontium ranelate
Lin et al. Weak bones in diabetes mellitus–an update on pharmaceutical treatment options
WO2015057836A2 (en) Bone anabolic parathyroid hormone and parathyroid hormone related-protein analogs
Alam et al. Chloroquine increases osteoclast activity in vitro but does not improve the osteopetrotic bone phenotype of ADO2 mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150121